{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:04:37Z","timestamp":1792789477575,"version":"4.5.0"},"reference-count":182,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medica Sur Clinic and Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Metabolic-dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is a highly prevalent metabolic disorder characterized by hepatic steatosis in conjunction with at least one cardiometabolic risk factor, such as obesity, type 2 diabetes, hypertension, or dyslipidemia. As global rates of obesity and metabolic syndrome continue to rise, MASLD is becoming a major public health concern, with projections indicating a substantial increase in prevalence over the coming decades. The disease spectrum ranges from simple steatosis to metabolic-dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and hepatocellular carcinoma, contributing to significant morbidity and mortality worldwide. This review delves into the molecular mechanisms driving MASLD pathogenesis, including dysregulation of lipid metabolism, chronic inflammation, oxidative stress, mitochondrial dysfunction, and gut microbiota alterations. Recent advances in research have highlighted the role of genetic and epigenetic factors in disease progression, as well as novel therapeutic targets such as peroxisome proliferator-activated receptors (PPARs), fibroblast growth factors, and thyroid hormone receptor beta agonists. Given the multifaceted nature of MASLD, a multidisciplinary approach integrating early diagnosis, molecular insights, lifestyle interventions, and personalized therapies is critical. This review underscores the urgent need for continued research into innovative treatment strategies and precision medicine approaches to halt MASLD progression and improve patient outcomes.<\/jats:p>","DOI":"10.3390\/ijms26072959","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T05:35:03Z","timestamp":1742880903000},"page":"2959","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["Metabolic-Dysfunction-Associated Steatotic Liver Disease: Molecular Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies"],"prefix":"10.3390","volume":"26","author":[{"given":"Jeysson E.","family":"Mej\u00eda-Guzm\u00e1n","sequence":"first","affiliation":[{"name":"Translational Research Unit, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n A.","family":"Belmont-Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Translational Research Unit, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico"},{"name":"Postgraduate Program in Experimental Biology, Divisi\u00f3n de Ciencias B\u00e1sicas y de la Salud (DCBS), Universidad Autonoma Metropolitana-Iztapalapa, Mexico City 09340, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7451-3306","authenticated-orcid":false,"given":"Norberto C.","family":"Ch\u00e1vez-Tapia","sequence":"additional","affiliation":[{"name":"Translational Research Unit, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico"},{"name":"Obesity and Digestive Diseases Unit, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6514-7869","authenticated-orcid":false,"given":"Misael","family":"Uribe","sequence":"additional","affiliation":[{"name":"Obesity and Digestive Diseases Unit, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Nu\u00f1o-L\u00e1mbarri","sequence":"additional","affiliation":[{"name":"Translational Research Unit, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico"},{"name":"Surgery Department, Faculty of Medicine, The National Autonomous University of Mexico (UNAM), Mexico City 04510, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.cgh.2023.11.003","article-title":"Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017\u20132020","volume":"22","author":"Kalligeros","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1111\/liv.15695","article-title":"Exploring the Landscape of Steatotic Liver Disease in the General US Population","volume":"43","author":"Ciardullo","year":"2023","journal-title":"Liver Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s43856-024-00649-x","article-title":"Disparities in Steatosis Prevalence in the United States by Race or Ethnicity According to the 2023 Criteria","volume":"4","author":"Lazarus","year":"2024","journal-title":"Commun. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"101127","DOI":"10.1016\/j.jhepr.2024.101127","article-title":"Characteristics and Long-Term Mortality of Individuals with MASLD, MetALD, and ALD, and the Utility of SAFE Score","volume":"6","author":"Sripongpun","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Fukushima, M., Miyaaki, H., Nakao, Y., Sasaki, R., Haraguchi, M., Takahashi, K., Ozawa, E., Miuma, S., Akazawa, Y., and Soyama, A. (2024). Characterizing Alcohol-Related and Metabolic Dysfunction-Associated Steatotic Liver Disease Cirrhosis via Fibrotic Pattern Analysis. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-73739-4"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1055\/s-0044-1785196","article-title":"New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice","volume":"44","author":"Canivet","year":"2024","journal-title":"Semin. Liver Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1111\/jgh.16554","article-title":"Impact of Nomenclature as Metabolic Associated Steatotic Liver Disease on Steatotic Liver Disease Prevalence and Screening: A Prospective Population Survey in Asians","volume":"39","author":"Wu","year":"2024","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients with Type 2 Diabetes","volume":"22","author":"Younossi","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global Prevalence, Incidence, and Outcomes of Non-Obese or Lean Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1007\/s00261-024-04285-w","article-title":"Differences in the Prevalence of NAFLD, MAFLD, and MASLD According to Changes in the Nomenclature in a Health Check-up Using MRI-Derived Proton Density Fat Fraction","volume":"49","author":"Park","year":"2024","journal-title":"Abdom. Radiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Amernia, B., Moosavy, S.H., Banookh, F., and Zoghi, G. (2021). FIB-4, APRI, and AST\/ALT Ratio Compared to FibroScan for the Assessment of Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease in Bandar Abbas, Iran. BMC Gastroenterol., 21.","DOI":"10.1186\/s12876-021-02038-3"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/joim.13343","article-title":"Risk for Hepatic and Extra-hepatic Outcomes in Nonalcoholic Fatty Liver Disease","volume":"292","author":"Kechagias","year":"2022","journal-title":"J. Intern. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","article-title":"American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr. Pract."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Theodorakis, N., and Nikolaou, M. (2025). From Cardiovascular-Kidney-Metabolic Syndrome to Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Proposing an Expanded Framework. Biomolecules, 15.","DOI":"10.3390\/biom15020213"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cld.2023.01.004","article-title":"Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease: Nonhepatocellular Cancers","volume":"27","author":"Ibrahim","year":"2023","journal-title":"Clin. Liver Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"101428","DOI":"10.1016\/j.molmet.2021.101428","article-title":"CD36 Promotes de Novo Lipogenesis in Hepatocytes through INSIG2-Dependent SREBP1 Processing","volume":"57","author":"Zeng","year":"2022","journal-title":"Mol. Metab."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"113721","DOI":"10.1016\/j.yexcr.2023.113721","article-title":"HBx Induced Upregulation of FATP2 Promotes the Development of Hepatic Lipid Accumulation","volume":"430","author":"Lu","year":"2023","journal-title":"Exp. Cell Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.immuni.2021.08.006","article-title":"A Subset of Kupffer Cells Regulates Metabolism through the Expression of CD36","volume":"54","author":"Barreby","year":"2021","journal-title":"Immunity"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e70472","DOI":"10.7554\/eLife.70472","article-title":"Hepatic MIR20B Promotes Nonalcoholic Fatty Liver Disease by Suppressing PPARA","volume":"10","author":"Lee","year":"2021","journal-title":"eLife"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"154661","DOI":"10.1016\/j.phymed.2023.154661","article-title":"Diosgenin Attenuates Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes through Regulating SIRT6-Related Fatty Acid Uptake","volume":"111","author":"Nie","year":"2023","journal-title":"Phytomedicine"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Dille, M., Nikolic, A., Wahlers, N., Fahlbusch, P., Jacob, S., Hartwig, S., Lehr, S., Kabra, D., Klymenko, O., and Al-Hasani, H. (2022). Long-Term Adjustment of Hepatic Lipid Metabolism after Chronic Stress and the Role of FGF21. Biochim. Biophys. Acta BBA\u2014Mol. Basis Dis., 1868.","DOI":"10.1016\/j.bbadis.2021.166286"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.1038\/s41467-021-27539-3","article-title":"The Methyltransferase METTL3 Negatively Regulates Nonalcoholic Steatohepatitis (NASH) Progression","volume":"12","author":"Li","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100138","DOI":"10.1016\/j.metop.2021.100138","article-title":"Deficiency of SREBP1c Modulates Autophagy Mediated Lipid Droplet Catabolism during Oleic Acid Induced Steatosis","volume":"12","author":"Sozen","year":"2021","journal-title":"Metab. Open"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Zhu, C., Huang, M., Kim, H.-G., Chowdhury, K., Gao, J., Liu, S., Wan, J., Wei, L., and Dong, X.C. (2021). SIRT6 Controls Hepatic Lipogenesis by Suppressing LXR, ChREBP, and SREBP1. Biochim. Biophys. Acta BBA\u2014Mol. Basis Dis., 1867.","DOI":"10.1016\/j.bbadis.2021.166249"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"102030","DOI":"10.1016\/j.molmet.2024.102030","article-title":"Improvement of MASLD and MASH by Suppression of Hepatic N-Acetyltransferase 10","volume":"89","author":"Yang","year":"2024","journal-title":"Mol. Metab."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Li, Y.-L., Li, L., Liu, Y.-H., Hu, L.-K., and Yan, Y.-X. (2023). Identification of Metabolism-Related Proteins as Biomarkers of Insulin Resistance and Potential Mechanisms of M6A Modification. Nutrients, 15.","DOI":"10.3390\/nu15081839"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Zywno, H., Bzdega, W., Kolakowski, A., Kurzyna, P., Harasim-Symbor, E., Sztolsztener, K., Chabowski, A., and Konstantynowicz-Nowicka, K. (2021). The Influence of Coumestrol on Sphingolipid Signaling Pathway and Insulin Resistance Development in Primary Rat Hepatocytes. Biomolecules, 11.","DOI":"10.3390\/biom11020268"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"101073","DOI":"10.1016\/j.jhepr.2024.101073","article-title":"Glycogen Synthase Kinase 3 Activity Enhances Liver Inflammation in MASH","volume":"6","author":"Khoury","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.4254\/wjh.v14.i7.1365","article-title":"Regulation of PPAR-\u03b3 Activity in Lipid-Laden Hepatocytes Affects Macrophage Polarization and Inflammation in Nonalcoholic Fatty Liver Disease","volume":"14","author":"Li","year":"2022","journal-title":"World J. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Theys, C., Vanderhaeghen, T., Van Dijck, E., Peleman, C., Scheepers, A., Ibrahim, J., Mateiu, L., Timmermans, S., Vanden Berghe, T., and Francque, S.M. (2024). Loss of PPAR\u03b1 Function Promotes Epigenetic Dysregulation of Lipid Homeostasis Driving Ferroptosis and Pyroptosis Lipotoxicity in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD). Front. Mol. Med., 3.","DOI":"10.3389\/fmmed.2023.1283170"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"R\u00e9gnier, M., Polizzi, A., Smati, S., Lukowicz, C., Fougerat, A., Lippi, Y., Fouch\u00e9, E., Lasserre, F., Naylies, C., and B\u00e9touli\u00e8res, C. (2020). Hepatocyte-Specific Deletion of Ppar\u03b1 Promotes NAFLD in the Context of Obesity. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-63579-3"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3350\/cmh.2024.0478","article-title":"USP29 Alleviates the Progression of MASLD by Stabilizing ACSL5 through K48 Deubiquitination","volume":"31","author":"Hu","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"100692","DOI":"10.1016\/j.jlr.2024.100692","article-title":"Lipotoxicity of Palmitic Acid Is Associated with DGAT1 Downregulation and Abolished by PPAR\u03b1 Activation in Liver Cells","volume":"65","author":"Moliterni","year":"2024","journal-title":"J. Lipid Res."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Selvaraj, R., Zehnder, S.V., Watts, R., Lian, J., Das, C., Nelson, R., and Lehner, R. (2023). Preferential Lipolysis of DGAT1 over DGAT2 Generated Triacylglycerol in Huh7 Hepatocytes. Biochim. Biophys. Acta BBA\u2014Mol. Cell Biol. Lipids, 1868.","DOI":"10.1016\/j.bbalip.2023.159376"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.cmet.2024.01.011","article-title":"DGAT2 Inhibition Blocks SREBP-1 Cleavage and Improves Hepatic Steatosis by Increasing Phosphatidylethanolamine in the ER","volume":"36","author":"Rong","year":"2024","journal-title":"Cell Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jhep.2021.09.008","article-title":"Inhibition of ATG3 Ameliorates Liver Steatosis by Increasing Mitochondrial Function","volume":"76","author":"Fondevila","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Jiang, J., Li, H., Tang, M., Lei, L., Li, H.-Y., Dong, B., Li, J.-R., Wang, X.-K., Sun, H., and Li, J.-Y. (2024). Upregulation of Hepatic Glutathione S-Transferase Alpha 1 Ameliorates Metabolic Dysfunction-Associated Steatosis by Degrading Fatty Acid Binding Protein 1. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25105086"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"100853","DOI":"10.1016\/j.jhepr.2023.100853","article-title":"Intestinal Pgc1\u03b1 Ablation Protects from Liver Steatosis and Fibrosis","volume":"5","author":"Piccinin","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"155272","DOI":"10.1016\/j.metabol.2022.155272","article-title":"CX3CL1\/CX3CR1 Interaction Protects against Lipotoxicity-Induced Nonalcoholic Steatohepatitis by Regulating Macrophage Migration and M1\/M2 Status","volume":"136","author":"Ni","year":"2022","journal-title":"Metabolism"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.3168\/jds.2022-23136","article-title":"Regulation of Cholesterol Metabolism during High Fatty Acid\u2013Induced Lipid Deposition in Calf Hepatocytes","volume":"106","author":"Yang","year":"2023","journal-title":"J. Dairy Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"101874","DOI":"10.1016\/j.molmet.2024.101874","article-title":"Conditional Hepatocyte Ablation of PDIA1 Uncovers Indispensable Roles in Both APOB and MTTP Folding to Support VLDL Secretion","volume":"80","author":"Chen","year":"2024","journal-title":"Mol. Metab."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1016\/j.molcel.2022.09.018","article-title":"Cytoplasmic SIRT6-Mediated ACSL5 Deacetylation Impedes Nonalcoholic Fatty Liver Disease by Facilitating Hepatic Fatty Acid Oxidation","volume":"82","author":"Hou","year":"2022","journal-title":"Mol. Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.cmet.2021.05.006","article-title":"TMEM41B Acts as an ER Scramblase Required for Lipoprotein Biogenesis and Lipid Homeostasis","volume":"33","author":"Huang","year":"2021","journal-title":"Cell Metab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jacl.2023.08.009","article-title":"Missense Mutation Q384K in the APOB Gene Affecting the Large Lipid Transfer Module of ApoB Reduces the Secretion of ApoB-100 in the Liver without Reducing the Secretion of ApoB-48 in the Intestine","volume":"17","author":"Asprusten","year":"2023","journal-title":"J. Clin. Lipidol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s42255-020-00331-1","article-title":"Hepatocyte ATF3 Protects against Atherosclerosis by Regulating HDL and Bile Acid Metabolism","volume":"3","author":"Xu","year":"2021","journal-title":"Nat. Metab."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e0639","DOI":"10.1097\/HC9.0000000000000639","article-title":"Adipokines Regulate the Development and Progression of MASLD through Organellar Oxidative Stress","volume":"9","author":"Zhao","year":"2025","journal-title":"Hepatol. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Dong, Z., Zhuang, Q., Ye, X., Ning, M., Wu, S., Lu, L., and Wan, X. (2020). Adiponectin Inhibits NLRP3 Inflammasome Activation in Nonalcoholic Steatohepatitis via AMPK-JNK\/ErK1\/2-NF\u03baB\/ROS Signaling Pathways. Front. Med., 7.","DOI":"10.3389\/fmed.2020.546445"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Zhou, M., Xu, A., Tam, P.K.H., Lam, K.S.L., Huang, B., Liang, Y., Lee, I.-K., Wu, D., and Wang, Y. (2012). Upregulation of UCP2 by Adiponectin: The Involvement of Mitochondrial Superoxide and HnRNP K. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0032349"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jhep.2012.11.035","article-title":"Leptin Is Key to Peroxynitrite-Mediated Oxidative Stress and Kupffer Cell Activation in Experimental Non-Alcoholic Steatohepatitis","volume":"58","author":"Chatterjee","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"12553","DOI":"10.1073\/pnas.1006962107","article-title":"Fibroblast Growth Factor 21 Regulates Energy Metabolism by Activating the AMPK\u2013SIRT1\u2013PGC-1\u03b1 Pathway","volume":"107","author":"Chau","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11010-015-2358-6","article-title":"Fibroblast Growth Factor (FGF21) Protects Mouse Liver against d-Galactose-Induced Oxidative Stress and Apoptosis via Activating Nrf2 and PI3K\/Akt Pathways","volume":"403","author":"Yu","year":"2015","journal-title":"Mol. Cell. Biochem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.1210\/jc.2016-1320","article-title":"Retinol-Binding Protein 4 Induces Hepatic Mitochondrial Dysfunction and Promotes Hepatic Steatosis","volume":"101","author":"Liu","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.freeradbiomed.2022.12.085","article-title":"Exosomal RBP4 Potentiated Hepatic Lipid Accumulation and Inflammation in High-Fat-Diet-Fed Mice by Promoting M1 Polarization of Kupffer Cells","volume":"195","author":"Yao","year":"2023","journal-title":"Free Radic. Biol. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.cellsig.2015.04.010","article-title":"New Role of Irisin in Hepatocytes: The Protective Effect of Hepatic Steatosis in Vitro","volume":"27","author":"Park","year":"2015","journal-title":"Cell. Signal."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Batirel, S., Bozaykut, P., Mutlu Altundag, E., Kartal Ozer, N., and Mantzoros, C.S. (2014). The Effect of Irisin on Antioxidant System in Liver. Free Radic. Biol. Med., 75.","DOI":"10.1016\/j.freeradbiomed.2014.10.592"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Pohl, R., Feder, S., Haberl, E.M., Rein-Fischboeck, L., Weiss, T.S., Spirk, M., Bruckmann, A., McMullen, N., Sinal, C.J., and Buechler, C. (2022). Chemerin Overexpression in the Liver Protects against Inflammation in Experimental Non-Alcoholic Steatohepatitis. Biomedicines, 10.","DOI":"10.3390\/biomedicines10010132"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.2337\/db12-0232","article-title":"Vaspin Is an Adipokine Ameliorating ER Stress in Obesity as a Ligand for Cell-Surface GRP78\/MTJ-1 Complex","volume":"61","author":"Nakatsuka","year":"2012","journal-title":"Diabetes"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Li, C., Cheng, H., Adhikari, B.K., Wang, S., Yang, N., Liu, W., Sun, J., and Wang, Y. (2022). The Role of Apelin\u2013APJ System in Diabetes and Obesity. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.820002"},{"key":"ref_61","first-page":"484","article-title":"Serum Resistin Levels in Adult Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"9","author":"Han","year":"2021","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4021623","DOI":"10.1155\/2019\/4021623","article-title":"Visfatin Induces Inflammation and Insulin Resistance via the NF-\u03baB and STAT3 Signaling Pathways in Hepatocytes","volume":"2019","author":"Heo","year":"2019","journal-title":"J. Diabetes Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"233","DOI":"10.14740\/jocmr2761w","article-title":"Insulin-Like Growth Factor-1 Deficiency and Cirrhosis Establishment","volume":"9","year":"2017","journal-title":"J. Clin. Med. Res."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Lee, E., Kang, S., Lee, A.-R., Kim, J.H., Kim, T.W., Lee, J.E., and Kim, H.R. (2022). Stachydrine Derived from Fermented Rice Prevents Diet-Induced Obesity by Regulating Adipsin and Endoplasmic Reticulum Homeostasis. J. Nutr. Biochem., 107.","DOI":"10.1016\/j.jnutbio.2022.109036"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Gu, N., Wang, J., Di, Z., Liu, Z., Jia, X., Yan, Y., Chen, X., Zhang, Q., and Qian, Y. (2019). The Effects of Intelectin-1 on Antioxidant and Angiogenesis in HUVECs Exposed to Oxygen Glucose Deprivation. Front. Neurol., 10.","DOI":"10.3389\/fneur.2019.00383"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Skuratovskaia, D., Komar, A., Vulf, M., Quang, H.V., Shunkin, E., Volkova, L., Gazatova, N., Zatolokin, P., and Litvinova, L. (2021). IL-6 Reduces Mitochondrial Replication, and IL-6 Receptors Reduce Chronic Inflammation in NAFLD and Type 2 Diabetes. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22041774"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41467-020-20303-z","article-title":"Hepatocyte-Specific IL11 Cis-Signaling Drives Lipotoxicity and Underlies the Transition from NAFLD to NASH","volume":"12","author":"Dong","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.7150\/ijbs.63889","article-title":"SOCS2 Suppresses Inflammation and Apoptosis during NASH Progression through Limiting NF-\u039aB Activation in Macrophages","volume":"17","author":"Li","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"100701","DOI":"10.1016\/j.jlr.2024.100701","article-title":"Metallothionein 1B Attenuates Inflammation and Hepatic Steatosis in MASH by Inhibiting the AKT\/PI3K Pathway","volume":"66","author":"Guan","year":"2024","journal-title":"J. Lipid Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1172\/JCI121842","article-title":"STING-Mediated Inflammation in Kupffer Cells Contributes to Progression of Nonalcoholic Steatohepatitis","volume":"129","author":"Yu","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Wu, Y., Chen, Z., Fuda, H., Tsukui, T., Wu, X., Shen, N., Saito, N., Chiba, H., and Hui, S.-P. (2021). Oxidative Stress Linked Organ Lipid Hydroperoxidation and Dysregulation in Mouse Model of Nonalcoholic Steatohepatitis: Revealed by Lipidomic Profiling of Liver and Kidney. Antioxidants, 10.","DOI":"10.3390\/antiox10101602"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Rauchbach, E., Zeigerman, H., Abu-Halaka, D., and Tirosh, O. (2022). Cholesterol Induces Oxidative Stress, Mitochondrial Damage and Death in Hepatic Stellate Cells to Mitigate Liver Fibrosis in Mice Model of NASH. Antioxidants, 11.","DOI":"10.3390\/antiox11030536"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Vargas-Pozada, E.E., Ramos-Tovar, E., Rodriguez-Callejas, J.D., Cardoso-Lezama, I., Galindo-G\u00f3mez, S., Talam\u00e1s-Lara, D., V\u00e1squez-Garz\u00f3n, V.R., Arellanes-Robledo, J., Tsutsumi, V., and Villa-Trevi\u00f1o, S. (2022). Caffeine Inhibits NLRP3 Inflammasome Activation by Downregulating TLR4\/MAPK\/NF-\u039aB Signaling Pathway in an Experimental NASH Model. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23179954"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/j.clnu.2024.08.007","article-title":"FNDC4 Reduces Hepatocyte Inflammatory Cell Death via AMPK\u03b1 in Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"43","author":"Neira","year":"2024","journal-title":"Clin. Nutr."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"317","DOI":"10.5483\/BMBRep.2020.53.6.280","article-title":"GPx7 Ameliorates Non-Alcoholic Steatohepatitis by Regulating Oxidative Stress","volume":"53","author":"Kim","year":"2020","journal-title":"BMB Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"170422","DOI":"10.1016\/j.peptides.2020.170422","article-title":"Chemerin\/CMKLR1 Ameliorates Nonalcoholic Steatohepatitis by Promoting Autophagy and Alleviating Oxidative Stress through the JAK2-STAT3 Pathway","volume":"135","author":"An","year":"2021","journal-title":"Peptides"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.immuni.2020.08.004","article-title":"Osteopontin Expression Identifies a Subset of Recruited Macrophages Distinct from Kupffer Cells in the Fatty Liver","volume":"53","author":"Remmerie","year":"2020","journal-title":"Immunity"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.immuni.2020.04.001","article-title":"Niche-Specific Reprogramming of Epigenetic Landscapes Drives Myeloid Cell Diversity in Nonalcoholic Steatohepatitis","volume":"52","author":"Seidman","year":"2020","journal-title":"Immunity"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.immuni.2020.06.003","article-title":"Impaired Kupffer Cell Self-Renewal Alters the Liver Response to Lipid Overload during Non-Alcoholic Steatohepatitis","volume":"53","author":"Tran","year":"2020","journal-title":"Immunity"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1038\/s12276-024-01280-5","article-title":"The Foxo1-YAP-Notch1 Axis Reprograms STING-Mediated Innate Immunity in NASH Progression","volume":"56","author":"Xu","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/hep.30990","article-title":"Yes-Associated Protein in Kupffer Cells Enhances the Production of Proinflammatory Cytokines and Promotes the Development of Nonalcoholic Steatohepatitis","volume":"72","author":"Song","year":"2020","journal-title":"Hepatology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.mito.2020.12.010","article-title":"Mitochondrial Dysfunction as a Mechanistic Biomarker in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)","volume":"57","author":"Ajaz","year":"2021","journal-title":"Mitochondrion"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/hep.32324","article-title":"Compromised Hepatic Mitochondrial Fatty Acid Oxidation and Reduced Markers of Mitochondrial Turnover in Human NAFLD","volume":"76","author":"Moore","year":"2022","journal-title":"Hepatology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/15548627.2021.1920818","article-title":"Lipotoxicity Reduces DDX58\/Rig-1 Expression and Activity Leading to Impaired Autophagy and Cell Death","volume":"18","author":"Frietze","year":"2022","journal-title":"Autophagy"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Qin, Y., Teker, S., Cunza, N.L., Theusch, E., Yang, N., Venkatesan, L., Su, J., Krauss, R.M., Lakkaraju, A., and Mattis, A.N. (2024). Loss of TMEM55B Modulates Lipid Metabolism through Dysregulated Lipophagy and Mitochondrial Function. bioRxiv.","DOI":"10.1101\/2024.11.12.623285"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"101566","DOI":"10.1016\/j.molmet.2022.101566","article-title":"The Mitochondrial Fission Protein Drp1 in Liver Is Required to Mitigate NASH and Prevents the Activation of the Mitochondrial ISR","volume":"64","author":"Steffen","year":"2022","journal-title":"Mol. Metab."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"103996","DOI":"10.1016\/j.isci.2022.103996","article-title":"Prevention and Regression of Megamitochondria and Steatosis by Blocking Mitochondrial Fusion in the Liver","volume":"25","author":"Yamada","year":"2022","journal-title":"iScience"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Chen, M., Huang, F., Chen, B., Kang, J., Yao, Y., Liu, M., Li, Y., Li, Y., Zhou, T., and Peng, D. (2023). A Classical Herbal Formula Alleviates High-Fat Diet Induced Nonalcoholic Steatohepatitis (NASH) via Targeting Mitophagy to Rehabilitate Dysfunctional Mitochondria, Validated by UPLC-HRMS Identification Combined with in Vivo Experiment. Biomed. Pharmacother., 168.","DOI":"10.1016\/j.biopha.2023.115831"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.7150\/thno.69826","article-title":"AGK Regulates the Progression to NASH by Affecting Mitochondria Complex I Function","volume":"12","author":"Ding","year":"2022","journal-title":"Theranostics"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s12964-024-01666-y","article-title":"SIRT1 Regulates Hepatic Vldlr Levels","volume":"22","author":"Peyman","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2309683","DOI":"10.1080\/19490976.2024.2309683","article-title":"Phocaeicola vulgatus Alleviates Diet-Induced Metabolic Dysfunction-Associated Steatotic Liver Disease Progression by Downregulating Histone Acetylation Level via 3-HPAA","volume":"16","author":"Jin","year":"2024","journal-title":"Gut Microbes"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Roy, S., Saha, P., Bose, D., Trivedi, A., More, M., Xiao, S., Diehl, A.M., and Chatterjee, S. (2023). Hepatic NLRP3-Derived Hsp70 Binding to TLR4 Mediates MASLD to MASH Progression upon Inhibition of PP2A by Harmful Algal Bloom Toxin Microcystin, a Second Hit. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242216354"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12986-020-0434-8","article-title":"Oleic Acid Ameliorates Palmitic Acid Induced Hepatocellular Lipotoxicity by Inhibition of ER Stress and Pyroptosis","volume":"17","author":"Zeng","year":"2020","journal-title":"Nutr. Metab."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Kochumon, S., Malik, M.Z., Sindhu, S., Arefanian, H., Jacob, T., Bahman, F., Nizam, R., Hasan, A., Thomas, R., and Al-Rashed, F. (2024). Gut Dysbiosis Shaped by Cocoa Butter-Based Sucrose-Free HFD Leads to Steatohepatitis, and Insulin Resistance in Mice. Nutrients, 16.","DOI":"10.3390\/nu16121929"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.21037\/atm-21-4012","article-title":"TLR2 Inhibition Ameliorates the Amplification Effect of LPS on Lipid Accumulation and Lipotoxicity in Hepatic Cells","volume":"9","author":"Zhang","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3","DOI":"10.15421\/022201","article-title":"Specificities of Lipotoxicity of Free Fatty Acids and Cytokine Profile in Patients with Chronic Diffuse Liver Diseases","volume":"13","author":"Didenko","year":"2021","journal-title":"Regul. Mech. Biosyst."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1002\/jcp.30218","article-title":"Ghrelin Ameliorates Nonalcoholic Steatohepatitis Induced by Chronic Low-grade Inflammation via Blockade of Kupffer Cell M1 Polarization","volume":"236","author":"Yin","year":"2021","journal-title":"J. Cell Physiol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5582\/bst.2024.01097","article-title":"Suppression of STK39 Weakens the MASLD\/MASH Process by Protecting the Intestinal Barrier","volume":"18","author":"Xu","year":"2024","journal-title":"Biosci. Trends"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41419-023-05853-6","article-title":"Butyrate Limits Inflammatory Macrophage Niche in NASH","volume":"14","author":"Sarkar","year":"2023","journal-title":"Cell Death Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e28123","DOI":"10.1016\/j.heliyon.2024.e28123","article-title":"Spleen Volume Is Independently Associated with Non-Alcoholic Fatty Liver Disease, Liver Volume and Liver Fibrosis","volume":"10","author":"Helgesson","year":"2024","journal-title":"Heliyon"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13244-024-01727-3","article-title":"The Impact of Hepatic and Splenic Volumetric Assessment in Imaging for Chronic Liver Disease: A Narrative Review","volume":"15","author":"Kutaiba","year":"2024","journal-title":"Insights Imaging"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1002\/hep.32782","article-title":"CD11b + CD43 Hi Ly6C Lo Splenocyte-Derived Macrophages Exacerbate Liver Fibrosis via Spleen-Liver Axis","volume":"77","author":"Zhang","year":"2023","journal-title":"Hepatology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e2318619121","DOI":"10.1073\/pnas.2318619121","article-title":"The Fatty Liver Disease\u2013Causing Protein PNPLA3-I148M Alters Lipid Droplet\u2013Golgi Dynamics","volume":"121","author":"Sherman","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e168476","DOI":"10.1172\/jci.insight.168476","article-title":"MiR-33 Deletion in Hepatocytes Attenuates MASLD-MASH-HCC Progression","volume":"9","author":"Cardelo","year":"2024","journal-title":"JCI Insight"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Theys, C., Ibrahim, J., Mateiu, L., Mposhi, A., Garc\u00eda-Pupo, L., De Pooter, T., De Rijk, P., Strazisar, M., \u0130nce, \u0130.A., and Vintea, I. (2023). Mitochondrial GpC and CpG DNA Hypermethylation Cause Metabolic Stress-Induced Mitophagy and Cholestophagy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242216412"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/hep4.1581","article-title":"Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes","volume":"4","author":"Younossi","year":"2020","journal-title":"Hepatol. Commun."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.cgh.2022.04.023","article-title":"The Potential Role of Fatigue in Identifying Patients with NASH and Advanced Fibrosis Who Experience Disease Progression","volume":"21","author":"Younossi","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"101480","DOI":"10.1016\/j.aohep.2024.101480","article-title":"Occult Liver Disease: A Multinational Perspective","volume":"29","author":"Chalasani","year":"2024","journal-title":"Ann. Hepatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s40271-020-00485-w","article-title":"Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study","volume":"14","author":"Doward","year":"2020","journal-title":"Patient"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"102849","DOI":"10.1016\/j.dsx.2023.102849","article-title":"Role of Semaglutide in the Treatment of Nonalcoholic Fatty Liver Disease or Non-Alcoholic Steatohepatitis: A Systematic Review and Meta-Analysis","volume":"17","author":"Bandyopadhyay","year":"2023","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1111\/liv.15437","article-title":"The Impact of Fatigue on Mortality of Patients with Non-alcoholic Fatty Liver Disease: Data from National Health and Nutrition Examination Survey 2005\u20132010 and 2017\u20132018","volume":"42","author":"Younossi","year":"2022","journal-title":"Liver Int."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Lee, H.A., Lee, H.A., and Kim, H.Y. (2024). Evolution of Characteristics of MASLD with and without Diabetes: A Meta-Analysis of Placebo Arms. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-79428-6"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Yang, K., Chen, J., Zhang, T., Yuan, X., Ge, A., Wang, S., Xu, H., Zeng, L., and Ge, J. (2022). Efficacy and Safety of Dietary Polyphenol Supplementation in the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.949746"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Rao, G., Peng, X., Li, X., An, K., He, H., Fu, X., Li, S., and An, Z. (2023). Unmasking the Enigma of Lipid Metabolism in Metabolic Dysfunction-Associated Steatotic Liver Disease: From Mechanism to the Clinic. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1294267"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"7273","DOI":"10.1002\/fsn3.4348","article-title":"Impact of Silymarin-supplemented Cookies on Liver Enzyme and Inflammatory Markers in Non-alcoholic Fatty Liver Disease Patients","volume":"12","author":"Jaffar","year":"2024","journal-title":"Food Sci. Nutr."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/liv.14118","article-title":"Accuracy of Imaging Methods for Steatohepatitis Diagnosis in Non-alcoholic Fatty Liver Disease Patients: A Systematic Review","volume":"39","author":"Besutti","year":"2019","journal-title":"Liver Int."},{"key":"ref_118","first-page":"503","article-title":"Non-Alcoholic Fatty Liver Disease Diagnosis with Multi-Group Factors","volume":"305","author":"Arzehgar","year":"2023","journal-title":"Stud. Health Technol. Inform."},{"key":"ref_119","first-page":"100992","article-title":"Cognitive Dysfunction in Early Experimental Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Systemic Inflammation and Neuroinflammation","volume":"6","author":"Mikkelsen","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/SGA.0000000000000753","article-title":"Impact of Mediterranean Dietary Education on Symptoms for Adults at Risk for Nonalcoholic Fatty Liver Disease","volume":"46","author":"Jerome","year":"2023","journal-title":"Gastroenterol. Nurs."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"101778","DOI":"10.1016\/j.aohep.2025.101778","article-title":"The Rationale for the Aggressive Progression of MASLD in Patients with Type 2 Diabetes","volume":"30","year":"2025","journal-title":"Ann. Hepatol."},{"key":"ref_122","first-page":"267","article-title":"The Diagnostic and Initial Approach of the Patient with Non-Alcoholic Fatty Liver Disease: Role of the Primary Care Provider","volume":"12","author":"Uribe","year":"2019","journal-title":"Gastroenterol. Hepatol. Bed Bench"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2211349","DOI":"10.1080\/07853890.2023.2211349","article-title":"Nonalcoholic Steatohepatitis Diagnosis and Treatment from the Perspective of Patients and Primary Care Physicians: A Cross-Sectional Survey","volume":"55","author":"Nadolsky","year":"2023","journal-title":"Ann. Med."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Mascar\u00f3, C.M., Bouzas, C., Montemayor, S., Casares, M., G\u00f3mez, C., Ugarriza, L., Borr\u00e0s, P.-A., Mart\u00ednez, J.A., and Tur, J.A. (2022). Association between Stages of Hepatic Steatosis and Physical Activity Performance in Adults with Metabolic Syndrome: A Cross-Sectional Analysis in FLIPAN Study. Nutrients, 14.","DOI":"10.3390\/nu14091790"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) Score for the Non-Invasive Identification of Patients with Non-Alcoholic Steatohepatitis with Significant Activity and Fibrosis: A Prospective Derivation and Global Validation Study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.cld.2023.01.018","article-title":"Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease: Cardiovascular Diseases","volume":"27","author":"Armandi","year":"2023","journal-title":"Clin. Liver Dis."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"101741","DOI":"10.1016\/j.aohep.2024.101741","article-title":"A Social Media Listening Study of Patients\u2019 Experiences Relating to Metabolic Dysfunction-Associated Steatotic Liver Disease: The LISTEN-MASLD Study","volume":"30","author":"Lazarus","year":"2024","journal-title":"Ann. Hepatol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12937-021-00694-5","article-title":"Effects of Supplementation with Main Coffee Components Including Caffeine and\/or Chlorogenic Acid on Hepatic, Metabolic, and Inflammatory Indices in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial","volume":"20","author":"Mansour","year":"2021","journal-title":"Nutr. J."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e2400338","DOI":"10.1002\/mnfr.202400338","article-title":"Coffee Bioactive N-Methylpyridinium: Unveiling Its Antilipogenic Effects by Targeting De Novo Lipogenesis in Human Hepatocytes","volume":"68","author":"Giannotti","year":"2024","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"100254","DOI":"10.1016\/j.aohep.2020.08.071","article-title":"The Effect of Coffee Consumption on the Non-Alcoholic Fatty Liver Disease and Liver Fibrosis: A Meta-Analysis of 11 Epidemiological Studies","volume":"20","author":"Hayat","year":"2021","journal-title":"Ann. Hepatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4254\/wjh.v11.i2.138","article-title":"Bariatric Surgery in Patients with Non-Alcoholic Fatty Liver Disease\u2014From Pathophysiology to Clinical Effects","volume":"11","author":"Laursen","year":"2019","journal-title":"World J. Hepatol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric Surgery Provides Long-Term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/hep.32358","article-title":"Persistence of Severe Liver Fibrosis despite Substantial Weight Loss with Bariatric Surgery","volume":"76","author":"Pais","year":"2022","journal-title":"Hepatology"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1007\/s11695-025-07688-w","article-title":"Short-Term Evolution of MASLD Following Roux-En-Y Gastric Bypass: A Focus on Fibrotic MASH","volume":"35","author":"Echeverria","year":"2025","journal-title":"Obes. Surg."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/dom.16065","article-title":"Similar Weight Loss with Semaglutide Regardless of Diabetes and Cardiometabolic Risk Parameters in Individuals with Metabolic Dysfunction-associated Steatotic Liver Disease: Post Hoc Analysis of Three Randomised Controlled Trials","volume":"27","author":"Armstrong","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1080\/13696998.2024.2393952","article-title":"Budget Impact of Resmetirom for the Treatment of Adults with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis (Consistent with Stages F2 to F3 Fibrosis)","volume":"27","author":"Fishman","year":"2024","journal-title":"J. Med. Econ."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41575-024-01014-y","article-title":"A New Treatment and Updated Clinical Practice Guidelines for MASLD","volume":"22","author":"Powell","year":"2024","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.medj.2024.03.013","article-title":"Resmetirom, the Long-Awaited First Treatment for Metabolic Dysfunction-Associated Steatohepatitis and Liver Fibrosis?","volume":"5","year":"2024","journal-title":"Med"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e088862","DOI":"10.1136\/bmjopen-2024-088862","article-title":"Pemafibrate for Treating MASLD Complicated by Hypertriglyceridaemia: A Multicentre, Open-Label, Randomised Controlled Trial Study Protocol","volume":"14","author":"Iwaki","year":"2024","journal-title":"BMJ Open"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.cgh.2023.01.018","article-title":"Saroglitazar, a Dual PPAR \u03b1\/\u03b3 Agonist, Improves Atherogenic Dyslipidemia in Patients with Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis","volume":"21","author":"Siddiqui","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/dom.14623","article-title":"Efficacy and Safety of Evogliptin in Patients with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease: A Multicentre, Double-blind, Randomized, Comparative Trial","volume":"24","author":"Han","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1111\/dom.16198","article-title":"Effects of the SGLT2 Inhibitor Ipragliflozin and Metformin on Hepatic Steatosis and Liver Fibrosis: Sub-analysis of a Randomized Controlled Study","volume":"27","author":"Hirayama","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"108610","DOI":"10.1016\/j.jdiacomp.2023.108610","article-title":"Effect of Dapagliflozin on Liver and Pancreatic Fat in Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease","volume":"37","author":"Shi","year":"2023","journal-title":"J. Diabetes Complicat."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/jdi.14246","article-title":"Long-term Effects of Ipragliflozin and Pioglitazone on Metabolic Dysfunction-associated Steatotic Liver Disease in Patients with Type 2 Diabetes: 5 Year Observational Follow-up of a Randomized, 24 Week, Active-controlled Trial","volume":"15","author":"Ito","year":"2024","journal-title":"J. Diabetes Investig."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-022-01861-9","article-title":"Licogliflozin for Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study","volume":"28","author":"Harrison","year":"2022","journal-title":"Nat. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12933-024-02149-7","article-title":"Ipragliflozin and Sitagliptin Differentially Affect Lipid and Apolipoprotein Profiles in Type 2 Diabetes: The SUCRE Study","volume":"23","author":"Nagao","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/dom.14978","article-title":"Effects of Canagliflozin on Liver Steatosis and Fibrosis Markers in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Post Hoc Analysis of the CREDENCE Trial","volume":"25","author":"Koshino","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e40356","DOI":"10.1097\/MD.0000000000040356","article-title":"The Effect of Ertugliflozin in Patients with Nonalcoholic Fatty Liver Disease Associated with Type 2 Diabetes Mellitus: A Randomized Controlled Trial","volume":"103","author":"Khaliq","year":"2024","journal-title":"Medicine"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2021.10.018","article-title":"EDP-305 in Patients with NASH: A Phase II Double-Blind Placebo-Controlled Dose-Ranging Study","volume":"76","author":"Ratziu","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/joim.13531","article-title":"Current Treatment of Non-alcoholic Fatty Liver Disease","volume":"292","author":"Paternostro","year":"2022","journal-title":"J. Intern. Med."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jhep.2022.10.023","article-title":"Hepatic and Renal Improvements with FXR Agonist Vonafexor in Individuals with Suspected Fibrotic NASH","volume":"78","author":"Ratziu","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","article-title":"Safety and Efficacy of Combination Therapy with Semaglutide, Cilofexor and Firsocostat in Patients with Non-Alcoholic Steatohepatitis: A Randomised, Open-Label Phase II Trial","volume":"77","author":"Alkhouri","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/liv.15816","article-title":"Safety, Pharmacokinetics and Pharmacodynamics of Obeticholic Acid in Subjects with Fibrosis or Cirrhosis from NASH","volume":"44","author":"Alkhouri","year":"2024","journal-title":"Liver Int."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"e70021","DOI":"10.1002\/edm2.70021","article-title":"Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two-Centre Open, Single-Arm Trial","volume":"8","author":"Liu","year":"2024","journal-title":"Endocrinol. Diabetes Metab."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"108487","DOI":"10.1016\/j.diabres.2020.108487","article-title":"Liraglutide or Insulin Glargine Treatments Improves Hepatic Fat in Obese Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease in Twenty-Six Weeks: A Randomized Placebo-Controlled Trial","volume":"170","author":"Guo","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/dom.13907","article-title":"Exenatide and Dapagliflozin Combination Improves Markers of Liver Steatosis and Fibrosis in Patients with Type 2 Diabetes","volume":"22","author":"Gastaldelli","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1038\/s42255-023-00938-0","article-title":"Cotadutide Promotes Glycogenolysis in People with Overweight or Obesity Diagnosed with Type 2 Diabetes","volume":"5","author":"Parker","year":"2023","journal-title":"Nat. Metab."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/dom.15359","article-title":"Efficacy of Beinaglutide in the Treatment of Hepatic Steatosis in Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease: A Randomized, Open-label, Controlled Trial","volume":"26","author":"Fan","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/apt.18331","article-title":"Semaglutide 2.4\u2009mg in Participants with Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial","volume":"60","author":"Newsome","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","article-title":"Effect of Pemvidutide, a GLP-1\/Glucagon Dual Receptor Agonist, on MASLD: A Randomized, Double-Blind, Placebo-Controlled Study","volume":"82","author":"Harrison","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/apt.18042","article-title":"Randomised Clinical Trial: Design of the SYNERGY-NASH Phase 2b Trial to Evaluate Tirzepatide as a Treatment for Metabolic Dysfunction-associated Steatohepatitis and Modification of Screening Strategy to Reduce Screen Failures","volume":"60","author":"Vuppalanchi","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Phase 2a Trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jhep.2024.06.003","article-title":"Efficacy, Tolerability and Pharmacokinetics of Survodutide, a Glucagon\/Glucagon-like Peptide-1 Receptor Dual Agonist, in Cirrhosis","volume":"81","author":"Lawitz","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"107176","DOI":"10.1016\/j.cct.2023.107176","article-title":"A Phase 2, Adaptive Randomized, Double-Blind, Placebo-Controlled, Multicenter, 52-Week Study of HM15211 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis\u2014Study Design and Rationale of HM-TRIA-201 Study","volume":"130","author":"Abdelmalek","year":"2023","journal-title":"Contemp. Clin. Trials"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1111\/dom.15958","article-title":"The Impact of Vildagliptin as an Add-on Therapy on Matrix Metalloproteinase-14 Levels, Liver Stiffness and Subclinical Atherosclerosis in Adolescents with Type 1 Diabetes and Non-alcoholic Steatohepatitis: A Randomized Controlled Trial","volume":"26","author":"ElKabbany","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/dom.14004","article-title":"Dapagliflozin plus Saxagliptin Add-on to Metformin Reduces Liver Fat and Adipose Tissue Volume in Patients with Type 2 Diabetes","volume":"22","author":"Johansson","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cgh.2023.04.012","article-title":"Pegbelfermin in Patients with Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2B Study","volume":"22","author":"Abdelmalek","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/cpt.3046","article-title":"Population Pharmacokinetics and Pharmacodynamics of Pegozafermin in Patients with Nonalcoholic Steatohepatitis","volume":"114","author":"Tseng","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and Efficacy of Once-Weekly Efruxifermin versus Placebo in Non-Alcoholic Steatohepatitis (HARMONY): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 2b Trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/HEP.0000000000000607","article-title":"A Randomized, Double-Blind, Placebo-Controlled Trial of Aldafermin in Patients with NASH and Compensated Cirrhosis","volume":"79","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","article-title":"Safety and Efficacy of Long-Term Statin Treatment for Cardiovascular Events in Patients with Coronary Heart Disease and Abnormal Liver Tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: A Post-Hoc Analysis","volume":"376","author":"Athyros","year":"2010","journal-title":"Lancet"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"103126","DOI":"10.1016\/j.dsx.2024.103126","article-title":"Impact of Rosuvastatin on Metabolic Syndrome Patients with Moderate to Severe Metabolic Associated Fatty Liver Disease without Overt Diabetes: A Randomized Clinical Trial","volume":"18","author":"Wang","year":"2024","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"e31437","DOI":"10.1097\/MD.0000000000031437","article-title":"Effect of Metformin on Nonalcoholic Fatty Liver Based on Meta-Analysis and Network Pharmacology","volume":"101","author":"Huang","year":"2022","journal-title":"Medicine"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Phase 2b Trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat. Med."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Phase III STELLAR Trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/dom.14946","article-title":"A Phase 2a, Randomized, Double-blind, Placebo-controlled, Three-arm, Parallel-group Study to Assess the Efficacy, Safety, Tolerability and Pharmacodynamics of PF-06835919 in Patients with Non-alcoholic Fatty Liver Disease and Type 2 Diabetes","volume":"25","author":"Saxena","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/dom.15006","article-title":"Empagliflozin versus Sitagliptin for Ameliorating Intrahepatic Lipid Content and Tissue-specific Insulin Sensitivity in Patients with Early-stage Type 2 Diabetes with Non-alcoholic Fatty Liver Disease: A Prospective Randomized Study","volume":"25","author":"Hiruma","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_180","first-page":"7449","article-title":"A Randomized Controlled Trial Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxifylline on Egyptian Non-Alcoholic Steatohepatitis Patients","volume":"25","author":"Fouda","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"101185","DOI":"10.1016\/j.jhepr.2024.101185","article-title":"Lipid Metabolism in MASLD and MASH: From Mechanism to the Clinic","volume":"6","author":"Carli","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12944-024-02108-x","article-title":"Updated Mechanisms of MASLD Pathogenesis","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Dis."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/7\/2959\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:59:38Z","timestamp":1760029178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/7\/2959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":182,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["ijms26072959"],"URL":"https:\/\/doi.org\/10.3390\/ijms26072959","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]}}}